Gilead shouldn’t have to share the billions it reaped from its HIV prevention drugs with the federal government, the company told a federal judge.
The company denied that researchers with the Centers for Disease Control and Prevention “succeeded where others had not” in their development of the Pre-Exposure Prophylaxis (PrEP) treatment for preventing HIV, according to a response filed Thursday in the U.S. District Court for the District of Delaware. Gilead alleges the federal government isn’t entitled to a “reasonable royalty” for its work on the medication that became Truvada or that the CDC alone provided any “breakthrough work.”
Gilead’s ...